On December 16, 2024, FOSUN PHARMA, FOSUN NEW DRUG, and HENLIUS jointly announced that the proposal for the privatization of HENLIUS through a merger has met all the conditions precedent. The conditions include obtaining approvals or filings from relevant departments such as China's National Development and Reform Commission, Ministry of Commerce, and State Administration of Foreign Exchange.According to the announcement, comprehensive documents will be sent to shareholders on or before December 23, 2024. The merger agreement and supplemental merger agreement will still require fulfillment of other implementation conditions to take effect. The company reminds shareholders and potential investors that there remains uncertainty regarding the implementation of the merger, and it is advised to exercise caution when trading or buying company securities.The company suggests that relevant individuals with questions about the impact of the merger should consult professional advisors, including tax advisors regarding the tax consequences of share cancellation and the implementation of the merger.

On December 16, 2024, FOSUN PHARMA, FOSUN NEW DRUG, and HENLIUS jointly announced that the proposal for the privatization of HENLIUS through a merger has met all the conditions precedent. The conditions include obtaining approvals or filings from relevant departments such as China's National Development and Reform Commission, Ministry of Commerce, and State Administration of Foreign Exchange.According to the announcement, comprehensive documents will be sent to shareholders on or before December 23, 2024. The merger agreement and supplemental merger agreement will still require fulfillment of other implementation conditions to take effect. The company reminds shareholders and potential investors that there remains uncertainty regarding the implementation of the merger, and it is advised to exercise caution when trading or buying company securities.The company suggests that relevant individuals with questions about the impact of the merger should consult professional advisors, including tax advisors regarding the tax consequences of share cancellation and the implementation of the merger.